Neuromodulation

On March 19, 2025, the NHS Innovation Accelerator (NIA) announced 28 new innovators (“Fellows”) with healthcare solutions awarded to join the program in 2025. NIA provides intensive, tailored support to proven healthcare solutions, helping to accelerate their adoption and maximize their impact across the NHS. Awarded innovations concern e-Health, in-vitro diagnostic, gynecology, neuromodulation, and sustainability.

In February 2025, SBRI Healthcare, funded by the NHS Accelerated Access Collaborative, announced the results of three competitions. Funding of £1.3m was allocated for the development of 14 innovations that support women’s health, £1m for the development of 11 innovations that improve infection prevention and control to mitigate the spread of antimicrobial resistance, and £3 million to support four innovations that improve the health and well-being of children and young people who have asthma, epilepsy, or diabetes.

On January 30, 2025, the Institute for the Hospital Remuneration System (InEK) published the list of requests for innovation funding (NUB) submitted by hospitals in 2024. The medical technologies of cardiovascular, endoscopy, extracorporeal, gastrointestinal, neuromodulation, peripheral vascular, and other technology groups obtained positive status 1.

In January 2025, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedures Guidance (Transperineal laser ablation for lower urinary tract symptoms of benign prostatic hyperplasia, electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder) and one new Early Value Assessment (Artificial intelligence technologies to help detect fractures on X-rays in urgent care). Furthermore, one new clinical guideline was published, and one was updated.

On January 16, 2025, NHS England published an updated work plan for specialized clinical commissioning policies production. One Med Tech-related policy in the neuromodulation field was added to the work plan. No policies have been published since the previous update.

In October 2024, the Norwegian Directorate of Health released the Norwegian Clinical Procedure Coding (NKPK) system for 2025. A total of 15 new codes were introduced concerning cardiovascular, interventional radiology, neuromodulation, pulmonary, surgical procedures, and spine fields.

In August 2024, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedures Guidance concerning caval valve implantation for tricuspid regurgitation and phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury and for congenital central hypoventilation syndrome. Furthermore, two new clinical guidelines were published for diabetic retinopathy and adrenal insufficiency.

In August 2024, NICE prioritization board decisions were published regarding the following Med Tech-related topics: clinical guidelines on lower urinary tract symptoms in men (prioritized), NPi-200 for pupillary light reflex in critical care (not prioritized), Aquablation robotic therapy in benign prostatic hyperplasia (not prioritized), and tumor treating fields in glioblastoma (not prioritized).

In September 2024, the Canary Islands Healthcare Evaluation Service (SESCS) is working on several HTAs, including evaluations in neuromodulation, IVD, and some other fields.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2024. Five recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, peripheral vascular, neuromodulation, orthopedic, and spine devices.

In the second quarter of 2024, the Dutch Healthcare Institute (ZIN) published four coverage positions on proton therapy in testicular cancer, pulmonary artery pressure remote monitoring in chronic heart failure and neuromodulation in polyneuropathy with positive recommendation for coverage under basic insurance package, and on physiotherapy and exercise therapy in primary care settings for lower back pain, which was not recommended for coverage under the basic insurance package.

On May 27, 2024, the Danish Health Technology Council released two new publications: an evaluation of Optune® (Novocure) and a major analysis on the treatment of obstructive sleep apnea.